Skip to content

OS Therapies OSTX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Immunome logo
ImmunomeIMNM
$619.79M+80.9%
CTO
Citius Oncology, Inc.CTOR
$100.7M+10.1%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$99.89M-27.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$997M-13.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$646.64M+113%
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
$127.23M-45.6%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's total liabilities & equity?
OS Therapies (OSTX) reported total liabilities & equity of $7.3M in Q1 2026.
How has OS Therapies's total liabilities & equity changed year-over-year?
OS Therapies's total liabilities & equity increased by 71.7% year-over-year, from $4.25M to $7.3M.
What is the long-term trend for OS Therapies's total liabilities & equity?
Over 2 years (2023 to 2025), OS Therapies's total liabilities & equity has grown at a 192.7% compound annual growth rate (CAGR), from $798.08K to $6.84M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.